Tamoxifen has long been used in breast cancer, both in the adjuvant and preventive setting, but uptake and adherence are notoriously low, mainly because of adverse events. Using a much lower dose to ...

Based on the above rationale, a clinical trial assessing the efficacy and tolerability of the antiestrogen tamoxifen (‘Nolvadex’) 20 mg and the aromatase inhibitor anastrozole (‘Arimidex’) 1 mg both ...